Wang X, et al. - Experts aspired to evaluate whether older, Asian or severely affected patients with acute ischemic stroke (AIS) who were considered at high risk of thrombolysis could benefit more from low-dose rather than standard-dose alteplase treatment. They found that in key demographic subgroups of patients with AIS, the effects of low-dose alteplase were not clearly superior to the effects of standard-dose alteplase on death or disability. To identify patients with AIS who could benefit from low-dose alteplase, further investigation was needed.